Cyprotex - Pharmacokinetic specialists

Home \| About Us \| Investor Relations \| Products & Services \| Science & Technology \| People \| News & Events \| Contact Us News \| Events


Search our site:

	30 September 2003 Interim Results for the six months ended 30 June 2003 Cyprotex PLC, a drug discovery and technology information company, today reports its Interim Results for the six month period ended 30 June 2003. Highlights revenue of £368,804 a 12% increase over the same six-month period in 2002 reduced operating loss of £1.08 million, compared to a loss of £1.46 million in the same six-month period of 2002 received blue chip validation via 13 revenue generating contracts with, amongst others, Roche, Astra Zeneca and Avidex significant business discussions underway with 19 major global pharmaceutical companies appointment of Robert Morrisson Atwater as Chairman and Chief Executive Officer Commenting on the Results, Robert Morrisson Atwater, Chairman & Chief Executive of Cyprotex PLC, said: "I have joined Cyprotex at an exciting time. The Group has developed leading edge technology and put in place a high quality team of scientists, modellers and business developers, who have delivered promptly and effectively to all customers. I look forward to working with the team, building on the platform created and helping to deliver new business opportunities in the coming months."